Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Doyle

Showing results (531-540 of 617) with videos related to

Pageof 62
Sort By:
Trials|June 17, 2024
Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled studyParveen Fathima, Mark Jones, Reena D'Souza, et al.
The Journal of Antimicrobial Chemotherapy|August 6, 2016
The impact of a multidisciplinary antimicrobial stewardship team on the timeliness of antimicrobial therapy in patients with positive blood cultures: a randomized controlled trialKelly A Cairns, Joseph S Doyle, Janine M Trevillyan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 1, 2019
Pharmacological activation of peroxisome proliferator-activated receptor γ (PPAR-γ) protects against hypoxia-associated fetal growth restrictionSydney L Lane, R Blair Dodson, Alexandrea S Doyle, et al.
The International Journal on Drug Policy|March 22, 2026
It's Your Right - implementation and outcomes of a co-designed national Australian hepatitis C health promotion campaignLouisa Walsh, Shannon Christensen, Troy Combo, et al.
Addiction (Abingdon, England)|March 14, 2023
The impacts of COVID-19 measures on drug markets and drug use among a cohort of people who use methamphetamine in Victoria, AustraliaKasun Rathnayake, Paul A Agius, Bernadette Ward, et al.
Eclinicalmedicine|March 5, 2024
Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysisMark J Hayes, Emma Beavon, Michael W Traeger, et al.
Open Forum Infectious Diseases|August 18, 2023
Incidence and Prevalence of Hepatitis C Virus Among HIV-Negative Gay and Bisexual Men Using HIV Pre-exposure Prophylaxis (PrEP): A Systematic Review and Meta-analysisMichael W Traeger, Brendan L Harney, Rachel Sacks-Davis, et al.
Antimicrobial Agents and Chemotherapy|April 14, 2010
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infectionPatricia S Doyle, Chiung-Kuang Chen, Jonathan B Johnston, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2014
Effects of HIV antiretroviral therapy on sexual and injecting risk-taking behavior: a systematic review and meta-analysisJoseph S Doyle, Louisa Degenhardt, Alisa E Pedrana, et al.
Journal of Medicinal Chemistry|January 22, 2010
Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapyKatrien Brak, Iain D Kerr, Kimberly T Barrett, et al.
Pageof 62

Showing results (531-540 of 617) with videos related to

Sort By:
Pageof 62
Trials|June 17, 2024
Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled studyParveen Fathima, Mark Jones, Reena D'Souza, et al.
The Journal of Antimicrobial Chemotherapy|August 6, 2016
The impact of a multidisciplinary antimicrobial stewardship team on the timeliness of antimicrobial therapy in patients with positive blood cultures: a randomized controlled trialKelly A Cairns, Joseph S Doyle, Janine M Trevillyan, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 1, 2019
Pharmacological activation of peroxisome proliferator-activated receptor γ (PPAR-γ) protects against hypoxia-associated fetal growth restrictionSydney L Lane, R Blair Dodson, Alexandrea S Doyle, et al.
The International Journal on Drug Policy|March 22, 2026
It's Your Right - implementation and outcomes of a co-designed national Australian hepatitis C health promotion campaignLouisa Walsh, Shannon Christensen, Troy Combo, et al.
Addiction (Abingdon, England)|March 14, 2023
The impacts of COVID-19 measures on drug markets and drug use among a cohort of people who use methamphetamine in Victoria, AustraliaKasun Rathnayake, Paul A Agius, Bernadette Ward, et al.
Eclinicalmedicine|March 5, 2024
Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysisMark J Hayes, Emma Beavon, Michael W Traeger, et al.
Open Forum Infectious Diseases|August 18, 2023
Incidence and Prevalence of Hepatitis C Virus Among HIV-Negative Gay and Bisexual Men Using HIV Pre-exposure Prophylaxis (PrEP): A Systematic Review and Meta-analysisMichael W Traeger, Brendan L Harney, Rachel Sacks-Davis, et al.
Antimicrobial Agents and Chemotherapy|April 14, 2010
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infectionPatricia S Doyle, Chiung-Kuang Chen, Jonathan B Johnston, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2014
Effects of HIV antiretroviral therapy on sexual and injecting risk-taking behavior: a systematic review and meta-analysisJoseph S Doyle, Louisa Degenhardt, Alisa E Pedrana, et al.
Journal of Medicinal Chemistry|January 22, 2010
Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapyKatrien Brak, Iain D Kerr, Kimberly T Barrett, et al.
Pageof 62